In a phase 3 trial of 218 adults with newly diagnosed relapsing MS, rituximab was non-inferior to ocrelizumab for no new or enlarging T2 MRI lesions from months 6 to 24 (estimated 92.2% vs 94.8%); infections were more common with rituximab (82% vs 69%).
RCTn = 218
Torkildsen et al. Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis